Xencor, Inc. $XNCR Shares Acquired by BVF Inc. IL

BVF Inc. IL grew its position in Xencor, Inc. (NASDAQ:XNCR) by 160.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,133,720 shares of the biopharmaceutical company’s stock after acquiring an additional 4,393,579 shares during the quarter. Xencor comprises approximately 3.7% of BVF Inc. IL’s portfolio, making the stock its 8th biggest position. BVF Inc. IL owned approximately 0.10% of Xencor worth $109,217,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of XNCR. AQR Capital Management LLC acquired a new stake in shares of Xencor in the first quarter valued at approximately $438,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Xencor by 9.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,047 shares of the biopharmaceutical company’s stock valued at $471,000 after acquiring an additional 3,692 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of Xencor by 89.9% in the first quarter. Goldman Sachs Group Inc. now owns 726,734 shares of the biopharmaceutical company’s stock valued at $7,732,000 after acquiring an additional 344,088 shares during the period. Creative Planning boosted its holdings in shares of Xencor by 25.3% in the second quarter. Creative Planning now owns 18,130 shares of the biopharmaceutical company’s stock valued at $143,000 after acquiring an additional 3,661 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Xencor by 170.9% in the second quarter. JPMorgan Chase & Co. now owns 330,007 shares of the biopharmaceutical company’s stock valued at $2,594,000 after acquiring an additional 208,182 shares during the period.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on XNCR shares. Zacks Research downgraded Xencor from a “hold” rating to a “strong sell” rating in a report on Wednesday, May 6th. JPMorgan Chase & Co. upped their price target on Xencor from $13.00 to $14.00 and gave the stock a “neutral” rating in a research note on Monday, May 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Xencor in a research note on Friday, March 27th. Barclays upped their price target on Xencor from $26.00 to $27.00 and gave the stock an “overweight” rating in a research note on Thursday, February 26th. Finally, Wall Street Zen cut Xencor from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 9th. Six analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $24.50.

Xencor Price Performance

Xencor stock opened at $12.78 on Thursday. Xencor, Inc. has a 12 month low of $6.92 and a 12 month high of $18.69. The business has a 50 day simple moving average of $12.10 and a 200-day simple moving average of $12.98. The stock has a market capitalization of $947.51 million, a PE ratio of -5.58 and a beta of 0.92.

Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.96). Xencor had a negative return on equity of 28.77% and a negative net margin of 177.10%.The company had revenue of $4.52 million for the quarter, compared to analysts’ expectations of $27.86 million. During the same quarter last year, the company earned ($0.66) EPS. Xencor’s revenue for the quarter was down 86.2% compared to the same quarter last year. As a group, equities research analysts anticipate that Xencor, Inc. will post -3.84 EPS for the current year.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.